[Summary] Supply of samples for the production of innovative drugs and clinical
Beijing InnoCare Pharma Tech Co., Ltd. (hereinafter referred to as "InnoCare") is a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of potential Best-In-Class and/or First-In-Class drugs for the treatment of cancer and autoimmune diseases.
InnoCare has strong independent innovation capabilities, holding numerous domestic and international invention patents and a rich product pipeline, applicable to lymphomas with high incidence among Chinese patients, liver cancer, cholangiocarcinoma, and other solid tumors, as well as autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. The company currently has 11 drug candidates, 4 of which are in the clinical stage. Among them, the New Drug Application (NDA) for orelabrutinib for the treatment of patients with relapsed/refractory CLL/SLL and relapsed/refractory MCL has been included in the priority review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China.
InnoCare was co-founded by Professor Shi Yigong, a world-renowned structural biologist, and Dr. Cui Jisong, an outstanding corporate manager in the biopharmaceutical industry. The company currently has nearly 500 employees, including more than a hundred scientific researchers. Core R&D personnel come from Fortune 500 companies such as Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Johnson & Johnson, and Bayer, and include multiple national, provincial, and municipal talent program experts. InnoCare's headquarters is located in Zhongguancun Life Science Park in Beijing, with R&D centers, project management centers, and production bases in Nanjing, Shanghai, and Guangzhou respectively, and branch offices in New Jersey and Boston in the United States for business cooperation and clinical trial management.
On March 23, 2020, InnoCare was officially listed on the Hong Kong Stock Exchange (HK9969). InnoCare's vision is to become a world-leading innovative drug company, leading China's innovative drug research and development into a new era.
What does Guangzhou InnoCare Pharma Technology Co., Ltd. require? Who is Guangzhou InnoCare Pharma Technology Co., Ltd. hiring? recruitment: 工厂生产类占比最多占50%，其次是生物/制药/化工/环保类占35.7%. What education can get in at ? 本科占比最多占57.1%，其次是大专占28.6%. High education required at ? 博士占7.1%. Work experience required at ? 不限占比最多占71.4%，其次是5-10年占21.4%. Where are the job locations at ? 广州占比最多占71.4%，其次是北京占21.4%. Based on job postings from the past year, for reference only.
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
